Apt Therapeutics, Inc.

Monsanto Technology LLC

Calgene Corporation

Renessen LLC

Humanzyme Limited

Monsanto Company

Astrazeneca Ab

Ridong Chen

Soon Seog Jeong

Timothy A Mitsky

Steven C Slater

Henry E Valentin

Yun-Hua Huang Wong

Sai S Subramaniam

Katherine Karberg

Jihong Liang

Lisa Marie Weaver

William D Rapp

Hui Feng

Lisa M Weaver

Steven Slater

This invention provides a new class of enhanced apyrases (EN-apyrases) with superior pharmacokinetic, pharmacodynamic, and pharmacochemical properties and which can be purified using simplified procedures. The invention further provides constructs for transforming a cell to produce these EN-apyrases. The EN-apyrase construct comprises sequences encoding a signal sequence, a linker, and a soluble apyrase. Also provided are preparations of apyrases and methods for producing apyrase in culture cells and purification thereof.

Therapeutic apyrase constructs, apyrase agents, and production methods

This invention provides new methods of treating subjects experiencing or at risk of bleeding due to vascular injury, especially to the microvasculature and/or platelet desensitization. Examples of injury usefully treated by apyrase agents are pathophysiological conditions, ischemia reperfusion injury, injury from pharmacologic agents such as anticoagulants, antiplatelet agents, antithrombotics, thrombolytics, and/or immunosuppressants, and injury resulting from transplantation. Apyrase agents are also useful to maintain organ function when said organs are transplanted into an allogeneic recipient.

Apyrase therapy for bleeding conditions

Nucleic acid sequences and methods are provided for producing plants and seeds having altered tocopherol content and compositions. The methods find particular use in increasing the tocopherol levels in plants, and in providing desirable tocopherol compositions in a host plant cell.

Nucleic acid sequences to proteins involved in tocopherol synthesis

The present invention relates to novel expression cassettes and vectors for efficiently producing authentic recombinant human proteins from stable cultures of novel human cell lines, the authentic recombinant proteins produced therefrom, and antibodies raised against those authentic recombinant proteins.

Recombinant production of authentic human proteins using human cell expression systems

The present invention provides for design and therapeutic use of ADPase enhanced polypeptides, pharmaceutical compositions, and methods useful for preventing and reversing platelet aggregation and recruitment for the treatment and prevention of vascular disorders in mammals.

Therapeutic use of ADPase enhanced apyrases

Design and therapeutic use of adpase enhanced apyrases

The present invention provides soluble forms of CD39L3 polypeptides and compositions, and methods useful inhibiting platelet activation and recruitment for the treatment and prevention of thrombotic disorders in mammals administered with soluble forms of CD39L3 polypeptides.

Therapeutic use of soluble CD39L3

The present invention provides transgenic plants transformed with an isolated DNA encoding a monomeric anthranilate synthase. The present invention also provides an isolated DNA encoding a monomeric anthranilate synthase from. Transformation vectors and transformed plants containing the isolated DNA and seeds derived therefrom, are also provided.

Transgenic high tryptophan plants

Growing community of inventors

Naperville, IL, United States of America

Ridong Chen